|
sherry. i believe the new trials about to begin will be in MBC metastatic breast cancer patients who have failed other regimens. one trial will be a phase 2 trial for patients with measurable disease who have failed tykerb. this will be a 3rd line setting trial. and could be registrational and thus approvable if and when the data shows superior efficacy to the tykerb. which should not be too difficult imo.
the other phase 2 trial is in a first line setting and is very exciting.
tras-dm1 vs herceptin + taxotere. to measure PFS
i have seen numbers for the H + T pfs around 6-7 months.. not very good. where as tras-dm1 has shown PFS around 9.6 months in early phase 1/2 trial data. approx 125 pts..
genentech is also comtemplating a pivotal phase 3 trial in a second line setting but i dont know any of the particulars yet.
sherry .. since you are NED. you would not be eligible for tdm1 . hopefully you wont ever need it.
run to live
|